Ad
ICPT Short Information Intercept Pharmaceuticals Inc.
home / stock / icpt / icpt short
Short Information | Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)
| Twenty Trading Day Totals | |
|---|---|
| Total Shorted Volume | 7,393,706 |
| Total Actual Volume | 39,690,965 |
| Short Trends | |
|---|---|
| Cover Days | 18 |
| Short Days | 0 |
| No Change Days | 2 |
| Averages | |
|---|---|
| Average Short Volume | 369,685 |
| Average Short Percentage | 17.60% |
Is there a ICPT Short Squeeze or Breakout about to happen?
See the ICPT Short Analysis for free Sign up or Login
Powered by Squeeze Report
ICPT Twenty Trading Day's Volume to Short Volume Chart
ICPT Twenty Trading Day Price Chart
ICPT Short Data Results Days
| Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
|---|---|---|---|---|---|---|---|
| 11-07-2023 | $19 | $19 | $19.01 | $18.98 | 3,963,455 | 276,294 | 6.97% |
| 11-06-2023 | $18.97 | $18.96 | $19.02 | $18.96 | 3,612,103 | 412,584 | 11.42% |
| 11-03-2023 | $18.97 | $18.98 | $18.985 | $18.95 | 1,027,785 | 166,538 | 16.2% |
| 11-02-2023 | $18.96 | $18.98 | $18.98 | $18.93 | 2,101,181 | 860,313 | 40.94% |
| 11-01-2023 | $18.93 | $18.96 | $18.96 | $18.93 | 2,278,951 | 1,005,502 | 44.12% |
| 10-31-2023 | $18.92 | $18.93 | $18.95 | $18.92 | 1,167,064 | 89,301 | 7.65% |
| 10-30-2023 | $18.91 | $18.92 | $18.96 | $18.91 | 703,909 | 157,525 | 22.38% |
| 10-27-2023 | $18.91 | $18.91 | $18.94 | $18.9 | 873,776 | 184,118 | 21.07% |
| 10-26-2023 | $18.92 | $18.94 | $18.95 | $18.89 | 1,910,541 | 86,466 | 4.53% |
| 10-25-2023 | $18.76 | $18.82 | $18.84 | $18.76 | 655,332 | 143,894 | 21.96% |
| 10-24-2023 | $18.77 | $18.82 | $18.92 | $18.77 | 1,017,295 | 123,188 | 12.11% |
| 10-23-2023 | $18.63 | $18.82 | $18.84 | $18.63 | 724,927 | 61,571 | 8.49% |
| 10-20-2023 | $18.63 | $18.67 | $18.72 | $18.63 | 871,393 | 56,417 | 6.47% |
| 10-19-2023 | $18.63 | $18.66 | $18.68 | $18.6 | 1,033,193 | 104,049 | 10.07% |
| 10-18-2023 | $18.62 | $18.61 | $18.7306 | $18.6 | 1,416,791 | 478,548 | 33.78% |
| 10-17-2023 | $18.61 | $18.62 | $18.66 | $18.56 | 1,579,195 | 154,549 | 9.79% |
| 10-16-2023 | $18.55 | $18.66 | $18.68 | $18.54 | 2,713,985 | 763,517 | 28.13% |
| 10-13-2023 | $18.94 | $18.2 | $18.94 | $17.015 | 7,806,206 | 1,639,594 | 21% |
| 10-12-2023 | $18.82 | $18.95 | $18.98 | $18.78 | 3,515,578 | 565,811 | 16.09% |
| 10-11-2023 | $18.66 | $18.73 | $18.735 | $18.66 | 718,305 | 63,927 | 8.9% |
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
0.0% G/L:
$19 Last:
3,963,455 Volume:
$19 Open:
$19 Close:
Intercept Pharmaceuticals Inc. Website:
Ad
-
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
-
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
-
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...